The Fund aims to provide long term capital and income growth by investing predominantly in the UK. The Fund will invest predominantly in UK equities, fixed interest and other securities. The Authorised Corporate Director may also invest at its discretion in other transferable securities, money market instruments, deposits, cash and near cash and collective investment schemes.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 4.6% |
Standard Life Investments UK Equity Unconstrained Class I | 4.5% |
Vodafone Group | 4.3% |
BP | 4.2% |
Vodafone Group | 4.2% |
British American Tobacco | 3.4% |
Aberforth UK Small Companies | 3.2% |
HSBC Holdings PLC (UK Reg) | 2.9% |
BG Group | 2.3% |
AstraZeneca | 2.3% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 4.6% |
Standard Life Investments UK Equity Unconstrained Class I | 4.5% |
Vodafone Group | 4.3% |
BP | 4.2% |
Other | 82.4% |
Date | 21-Nov-2024 |
---|---|
NAV | 78.23p |
Currency | GBP |
Change | 0.47p |
% | 0.60% |
YTD change | 3.57p |
YTD % | 4.78% |
Fund Inception | 28/02/1997 |
---|---|
Fund Manager | HSBC Multimanager |
TER | - |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | £100 |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | n/a |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.04 |
You are here: research